-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback